United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece


Several publicly funded clinical studies are conducted to characterise efficacy, toxicity and other aspects of this drug.

background logo AIDA-fine line
fp7-gen-rgb smallFP7 funded project MAGICBULLET: Optimisation of treatment with off-patent antimicrobial agents of ventilator-associated pneumonia
MagicBullet will carry out a randomized, open label, multicenter, non-inferiority phase IV clinical trial to compare safety and efficacy of colistin vs. meropenem, both combined with levofloxacin, for empirical treatment of VAP. A total of 496 patients will be included from 29 hospitals located in Spain, Italy, and Greece which are the most prevalent countries for infections caused by MDR-GNB.
background logo AIDA-fine line

NIAID (The National Institute of Allergy and Infectious Diseases, USA) funded a Randomized Controlled Clinical Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli comparing combination antimicrobial therapy with monotherapy for the treatment of Acinetobacter baumannii, a major cause of bloodstream infection and pneumonia in health care settings. This study has a similar study design as the AIDA clinical trial and will determine whether the treatment regimen of Colistimethate sodium combined with Imipenem-cilistatin is associated with a decreased risk for mortality compared to colistin alone for patients with bloodstream infection and/or pneumonia due to XDR-GNB. Secondary goal is to determine what treatment regimen (colistin monotherapy or colistin combined with imipenem) is more likely to reduce the emergence of colistin resistance among XDR-GNB isolates during therapy
Principal investigator is Keith Kaye, M.D., M.P.H., Wayne State University, Detroit
background logo AIDA-fine line

Observational Multinational Study (INCREMENT, Spanish Network for Research in Infectious Diseases): Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae

background logo AIDA-fine line

Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria
Poitiers University Hospital: This study determines the pharmacokinetics of colistin in patients receiving this drug.

background logo AIDA-fine line